Beautiful Virgin Islands

Thursday, Oct 02, 2025

Oxford Covid vaccine 'safe and effective' study shows

Oxford Covid vaccine 'safe and effective' study shows

The Oxford/AstraZeneca Covid vaccine is safe and effective, giving good protection, researchers have confirmed in The Lancet journal.

Most in the study were younger than 55, but the results so far indicate it does work well in older people too.

The data also suggest it can reduce spread of Covid, as well as protect against illness and death.

The paper, assessed by independent scientists, sets out full results from advanced trials of over 20,000 people.

Regulators, who will have seen the same data, are considering the jab for emergency use.

But there are still important questions about what dose to give, as well as who it will protect.

When the interim trial results were made public in a press release about a fortnight ago, the researchers reported three efficacy levels for the vaccine - an overall effectiveness of 70%, a lower one of 62% and a high of 90%.

That's because different doses of the vaccine were used in one part of the trial. Some volunteers were given shots that were half the strength than originally planned.

Yet that "wrong" dose turned out to be a winner - giving 90% protection - while two standard doses gave 62%.

The Lancet report reveals 1,367 people - out of many thousands in the trial - received the half dose followed by a full dose, which gave them 90% protection against getting ill with Covid-19.

The relatively small numbers means it is hard to draw firm conclusions.

None of that group were over the age of 55 though - and experts know it is older people who are most at risk of severe Covid illness.

In terms of safety, there was one severe adverse event potentially related to the vaccine and another one - a high temperature - that is still being investigated.

Both these participants are recovering and are still in the trial.

The study also measured protection against asymptomatic infection by asking volunteers to do regular swabs to check if they had Covid without feeling unwell.

More of these cases were seen in the group that did not receive the vaccine.

Pascal Soriot, chief executive officer for AstraZeneca said: "The results show that the vaccine is effective against Covid-19, with in particular no severe infections and no hospitalisations in the vaccine group, as well as safe and well tolerated.

"We have begun submitting data to regulatory authorities around the world for early approval and our global supply chains are up and running, ready to quickly begin delivering hundreds of millions of doses on a global scale at no profit."

Dr Charlie Weller, Head of Vaccines at Wellcome, said: "Today marks another key milestone in the Covid-19 vaccine journey.

"Although we await the trial completion and full data, it is highly encouraging to see the data behind the interim results announced last month, including an analysis of the different dosing regimens. This suggests that this vaccine could prevent asymptomatic disease."

AstraZeneca executive vice-president Sir Mene Pangalos said adults of all ages needed to be vaccinated to make a "dent" in the pandemic.

"I realise the people that are most severely impacted by disease are the over-65s, over-75s, over-85s, but the reality is we need to actually have vaccines that immunise everyone from adolescence to the oldest adults to really dent the pandemic around the world," he said.

Meanwhile, the UK has started a mass vaccination campaign with another Covid jab made by Pfizer/BioNTech.

On Tuesday Margaret Keenan, a 91-year-old grandmother, became the first person in the world to get the Pfizer Covid-19 jab as part of a mass vaccination programme..

The Oxford/AstraZeneca vaccine could also play a major role in fighting the pandemic if it is approved soon.

It is cheaper than some of the other Covid vaccines and easier to store and distribute.



The UK government has pre-ordered 100 million doses of the Oxford vaccine, which uses a harmless virus altered to look a lot more like the virus that causes Covid-19.

AstraZeneca says it will make three billion doses for the world next year.

Laura Foster explains why the Oxford vaccine matters


Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×